Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
Metrics: PDF 1634 views | HTML 2299 views | ?
Andrea Ghelli Luserna Di Rorà1, Ilaria Iacobucci1,*, Enrica Imbrogno1, Cristina Papayannidis1, Enrico Derenzini1, Anna Ferrari1, Viviana Guadagnuolo1, Valentina Robustelli1, Sarah Parisi1, Chiara Sartor1, Maria Chiara Abbenante1, Stefania Paolini1, Giovanni Martinelli1,*
1Institute of Hematology “L. e A. Seragnoli”, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
Ilaria Iacobucci, email: email@example.com
Giovanni Martinelli, email: firstname.lastname@example.org
Keywords: CHK1, cell cycle, acute lymphoblastic leukemia, DNA damage response, chemo-sensitizer agent
Received: February 12, 2016 Accepted: June 30, 2016 Published: July 11, 2016
During the last few years many Checkpoint kinase 1/2 (Chk1/Chk2) inhibitors have been developed for the treatment of different type of cancers. In this study we evaluated the efficacy of the Chk 1/2 inhibitor prexasertib mesylate monohydrate in B-/T- cell progenitor acute lymphoblastic leukemia (ALL) as single agent and in combination with other drugs. The prexasertib reduced the cell viability in a dose and time dependent manner in all the treated cell lines. The cytotoxic activity was confirmed by the increment of apoptotic cells (Annexin V/Propidium Iodide staining), by the increase of γH2A.X protein expression and by the activation of different apoptotic markers (Parp-1 and pro-Caspase3 cleavage). Furthermore, the inhibition of Chk1 changed the cell cycle profile. In order to evaluate the chemo-sensitizer activity of the compound, different cell lines were treated for 24 and 48 hours with prexasertib in combination with other drugs (imatinib, dasatinib and clofarabine). The results from cell line models were strengthened in primary leukemic blasts isolated from peripheral blood of adult acute lymphoblastic leukemia patients. In this study we highlighted the mechanism of action and the effectiveness of prexasertib as single agent or in combination with other conventional drugs like imatinib, dasatinib and clofarabine in the treatment of B-/T-ALL.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.